Presymptomatic testing for BRCA1 and BRCA2: how distressing are the pre-test weeks?

Presymptomatic DNA testing for autosomal dominant hereditary breast/ovarian cancer (HBOC) became an option after the identification of the BRCA1 and BRCA2 genes in 1994-1995. Healthy female mutation carriers have a high lifetime risk for breast cancer (56-87%) or ovarian cancer (10-60%) and may opt...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lodder, L, Frets, P, Trijsburg, R, Meijers-Heijboer, E, Klijn, J, Duivenvoorden, H, Tibben, A, Wagner, A, van der Meer, C A, Devilee, P, Cornelisse, C, Niermeijer, M, m other
Formato: Artigo
Idioma:English
Publicado em: BMJ Group 1999
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1734277/
https://ncbi.nlm.nih.gov/pubmed/10593998
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

https://ncbi.nlm.nih.gov/pmc/articles/PMC1734277/
https://ncbi.nlm.nih.gov/pubmed/10593998

Registos relacionados